International Multi-site Implementation of Local Cell-Free Protein Biomanufacturing to Advance Health and Research Equity

Limitations in global access to research and healthcare capacity undermine equity, sustainability, and resilience, particularly in resource-limited settings. Molecular diagnostics and biologic therapeutics are set to revolutionize medicine; however, our dependence on centralized biomanufacturing, and the concomitant cold chain logistics, restrict access to these benefits. While these constraints become particularly evident during global health crises, they reflect a chronic and unmet global challenge. Here, with research teams in North and South America and Asia, we challenge the conventional top-down paradigm by innovating community-driven solutions that empower underserved populations to actively participate in the bioeconomy, producing what they need, when, and where they need it. Our approach leverages decentralized, low-burden biomanufacturing technologies--built on cell-free protein synthesis and open-source hardware--to enable local, on-demand production of critical biologics, including high- value growth factors, vaccines, and diagnostic enzymes, demonstrating performance comparable to commercial gold standards. This platform, implemented at ten sites worldwide, supported patient trials targeting globally relevant pathogens, including SARS-CoV-2, chikungunya, and Oropouche viruses. Together, these initiatives lay the foundation for a new era of globally inclusive biomanufacturing, where innovation goes beyond geographic boundaries, and communities everywhere are empowered to respond to global challenges with enhanced speed, autonomy, and equity.